by Lori Solomon Patients with hemophilia A or B with inhibitors have a lower annualized bleeding rate with concizumab than with no prophylaxis, according to a phase 3 study published online Aug. 31 in the New England Journal of Medicine. Tadashi Matsushita, M.D., Ph.D., from Nagoya University Hospital in Japan, and colleagues evaluated the safety...
